Table 3 Summary of findings of the safety of CHW provision of DMPA in several countries of SSA and in some instances, in clinical settings
Safety | |||
|---|---|---|---|
Author, country | Mode of outcome measurement | Provider | Injection site morbidity |
Weidert et al. [10] Ethiopia | CHW reports | CHW | NR |
Okegbe et al. [4] Republic of Benin | CHW reports | CHW | NR |
Mwembo et al. [14] Democratic Republic of Congo | CHW reports | CHW | 40.6% |
Comfort et al. [17] Madagascar | CHW reports | CHW | NA |
Chin-quee et al. [15] Zambia | Client interview | CHW | 2% |
Hoke et al. [18] Madagascar | CHW reports | CHW | 3% |
Olawo et al. [23] Kenya | CHW reports | CHW | 0 |
FHI-USAID [24] Senegal | CHW reports | CHW | NR |
Krueger et al. [25] Uganda | Client registers | CHW CLINIC | 0 0 |
Prata et al. [21] Ethiopia | Client surveys at enrolment, 13th week and 6 months | CHW CLINIC | 2.1% 0.5% |
Stanback et al. [19] Uganda | Client surveys at enrolment, 13th week | CHW CLINIC | 0.7% 0.3% |
Poss et al. [20] Uganda | Client surveys at 3rd year | CHW CLINIC | NA NA |
Jacinto et al. [22] Mozambique | Client surveys at enrolment, 13th week and 6 months | CHW (TBA) CHW (APE) | < 0.5% |